Pharmabiz9m
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...
Pharmabiz39m
Lilly to establish new global capability centre in Hyderabad, India to hire over 1,000 skilled teams
Lilly to establish new global capability centre in Hyderabad, India to hire over 1,000 skilled teams: Our Bureau, Bengaluru Thursday, January 9, 2025, 15:30 Hrs [IST] Eli Lilly an ...